ImmunityBio Addresses FDA Concerns Over Advertising Practices

ImmunityBio has responded to recent correspondence from the U.S. Food and Drug Administration (FDA) regarding concerns over its advertising practices. The company stated that it remains committed to adhering to all regulatory requirements and ensuring compliance with FDA guidelines in its promotional activities.

The communication from the FDA reportedly highlighted specific issues related to ImmunityBio’s advertising materials, though details of the concerns were not disclosed publicly. In response, ImmunityBio confirmed that it is actively addressing the matters raised by the agency and reiterated its dedication to maintaining transparency and regulatory compliance in all aspects of its operations. The company emphasized its ongoing efforts to align with federal standards while continuing to provide information about its products responsibly.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 6, 2026

Author

GOAI